Ccl2 Mcp 1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CCL2 (Monocyte Chemoattractant Protein-1) is a small secreted chemokine that binds to CCR2 receptor to recruit monocytes and microglia to sites of inflammation. It is a key mediator of neuroinflammation in neurodegenerative diseases.
CCL2/MCP1 (Monocyte Chemoattractant Protein 1) is a pro-inflammatory chemokine that recruits monocytes, T cells, and dendritic cells to sites of inflammation. In the brain, CCL2 activates microglia and promotes neuroinflammation. Elevated CCL2 is observed in Alzheimer's disease and multiple sclerosis.
This protein is involved in:
| Attribute | Value |
|---|---|
| Protein Name | CCL2/MCP-1 |
| Gene | CCL2 |
| UniProt ID | P13500 |
| PDB Structures | 1DOM, 5D42, 5D43 |
| Molecular Weight | 11 kDa |
| Subcellular Localization | Secreted |
| Protein Family | C-C chemokine family |
The CCL2/MCP-1 protein belongs to the C-C chemokine family. The protein contains a carbohydrate-recognition domain (CRD).
CCL2/MCP-1 is involved in chemoattraction of monocytes and microglia to sites of injury.
CCL2/MCP-1 plays a role in AD pathogenesis through recruitment of microglia to amyloid plaques and promotion of neuroinflammation.
CCL2/MCP-1 contributes to PD through microglial recruitment to degenerating neurons.
The protein is implicated in multiple sclerosis and neuropathic pain.
| Drug/Approach | Target | Status | Description |
|---|---|---|---|
| Brilliant Blue G | P2X7 | Preclinical | Antagonist, reduces neuroinflammation |
| A-438079 | P2X7 | Preclinical | Antagonist, blocks channel opening |
| Anti-C1q antibodies | C1q | Clinical | Reduce complement-mediated damage |
| CCR2 antagonists | CCL2/CCR2 | Preclinical | Block monocyte recruitment |
| Galectin-3 inhibitors | LGALS3 | Preclinical | Reduce microglial activation |
The study of Ccl2 Mcp 1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CCL2/MCP-1 is expressed in various cell types in the brain:
Expression is typically low in healthy brain but increases dramatically in response to:
CCL2 signals through multiple pathways:
CCL2 has been investigated as a biomarker:
Key areas of ongoing research: